Synageva BioPharma, a Waltham, MA-based biotech firm with research and manufacturing operations in Athens, GA, says that it has closed a $30 million private equity financing and expects to raise more money in the weeks ahead. Baker Brothers Investments, a heathcare investment firm, led the financing, which included contributions from investment funds Tullis Dickerson and Four Partners. Synageva says that it is developing novel protein drugs and follow-on biologics, which are intended to be copies of existing biotech drugs.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
